

PHARMACOKINETICS OF CIPROFLOXACIN IN E.COLI NATURALLY INFECTED CHICKENS

By

Mohamed M. A. and Abd El-Hkeem M.M*

Dep of pharmacology, Animal Health Research Institute, Zagazig

** Dep of poultry Dis, Animal Health Research Institute, Zagazig*

ABSTRACT

Pharmacokinetic properties of ciprofloxacin were investigated in E.coli infected chickens after a single oral and Iv administration of 10 mg/kg b.wt. For oral administration, C_{max} was 0.510 $\mu\text{g/ml}$ at t_{max} 3.0 hours, C_{max} -to- MIC ratio was 16.346 and AUC-to-MIC ratio was 172.01. Also, K_e , $t_{0.5e}$, V_c , CL_B and bioavailability were 0.115h^{-1} , 6.026h, 12.270 L/kg, 1.411 L/kg and 75.9%, respectively. For Iv administration, β , $t_{0.5\beta}$, V_c and CL_B were 0.115h^{-1} , 6.026h, 3.463 L/Kg and 1.424 L/kg, respectively. Ciprofloxacin dose of 10 mg/kg b.wt. administered orally once daily to E.coli infected chickens would likely achieve the target ratios of C_{max} -to- MIC ratio greater than 10 necessary to minimize bacterial resistance and AUC- to - MIC ratio greater than 125 to maximize clinical and microbiological cures .

INTRODUCTION

Ciprofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that was developed exclusively for veterinary use. The fluoroquinolones are bactericidal and act principally by inhibition of bacterial DNA-gyrase which is necessary for supercoiling of DNA to provide a suitable spatial arrangement of DNA within the bacterial cell²⁹. Fluoroquinolones are active against a wide range of Gram-negative aerobes, a number of Gram-positive bacteria and mycoplasmas at low concentrations compared with other classes of antimicrobial agents (New, 1987 and Campoli-Richards *et al.*, 1988).

Results of recent studies have indicated that it is possible to choose the most effective dose and dosing schedule for administration of an antimicrobial on the basis of the pharmacodynamics (drug antibacterial

action versus concentration in serum) of the drug. Investigators testing multiple antimicrobial dosing regimens in animal infection models have determined that bactericidal effect occur by time-dependent or concentration-dependent mechanisms (Vogeleman *et al.*, 1988 and Leggett *et al.*, 1989). For antimicrobials (e.g. penicillins, cephalosporines and erythromycin) that kill by time-dependent mechanisms, the pharmacokinetic value that correlates with efficacy is the time that serum concentration remains above the minimum inhibitory concentration for the pathogen (4 to 8 times MIC). For antimicrobials (e.g. aminoglycosides and quinolones) with concentration-dependent killing, the peak serum concentration or the area under the concentration-time curve correlates best with efficacy in treatment.

Various pharmacokinetic aspects of flouroquinolones in normal and experimentally infected chickens have been studied (Baggot, 1980 and Atef *et al.*, 1992) but rare in naturally infected chickens obtained from poultry farms

The objective of this study is to determine the pharmacokinetic properties of ciprofloxacin after administration of single dose (10 mg / kg) either by oral or intravenous route in naturally infected chickens with E coli

Also, studying the relation between the pharmacokinetic properties of ciprofloxacin and MIC of the isolated E coli.

MATERIAL AND METHODS

Birds:

Laboratory diagnosis and pharmacokinetic study were conducted on fifteen, naturally infected hubbard broiler chickens of both sexes (35days old -1.5 kg average b. wt.). The chickens obtained from a poultry farm suspected to be infected with colibacillosis which diagnosed as E. coli infection during routine follow up in Animal Health Research Institute (Zagazig). Blood samples were collected from each bird and tested microbiologically (Bennett *et al.*, 1966 and Rosin *et al.*, 1989) to sure that they free from any antimicrobial agents.

Laboratory diagnosis:

The chicken are clinically investigated and symptoms were recorded as well as post - mortem examination was carried out and P.M. lesions (Sojka, 1965) were recorded. Organ samples were collected from heart blood, liver, spleen, air sacs and pericardial sacs for bacteriological examination using MaConkey agar, MaConkey broth and blood agar, then, incubated at 37°C for 24 hours. Suspected colonies of being E. Coli were subjected to morphological, biochemical as well as serological examination

(Edwards and Ewing, 1962; Sojka, 1965; Kauffman, 1969 and Cruickshank, 1972).

In vitro-sensitivity test and minimum inhibitory concentration:

Of the isolated E.coli was determined using agar plate diffusion⁵ and microdilution broth (Kolmer *et al.*, 1951 and Amsterdam, 1991) techniques, respectively.

Pharmacokinetics:

Single-dose pharmacokinetic properties of ciproflaxacin were studied in two groups of E.coli naturally infected chickens (n=5/group), one group was given orally ciprofloxacin at rate of (10 mg/kg. b.wt) and the other was given the same dose intravenous. Blood samples were collected at different time intervals as follows 0.1,0.25,0.5,0.75,1,2,3,4,6,8,10,12, and 24 hours after drug administration, centrifuged at 3000 rpm for 5 minutes, then, the serum was separated and stored at -20°C until assayed. Serum concentration of ciprofloxacin was determined by microbiological assay using bacillus subtilis (Bennett *et al.*, 1966 and Rosin *et al.*, 1989) ATCC 6633 as the test organism.

Data analysis:

Pharmacokinetic analysis (Baggot, 1980 and Metzler and Weiner, 1989) was carried out using one – compartment open model for oral administration and two –compartment open model for Iv administration in to statistical addition analysis (Rosin *et al.*, 1989).

RESULTS

Case investigation :

The diseased birds were examined clinically and respiratory symptoms were observed in the form of rattling sounds, coughing, gasping and rales. Also the examined birds showed listlessness and off food.

Postmortem examination was carried out on the dead birds which showed the presence of pericarditis, airsacculitis as well as liver, spleen and kidney congestion. Some birds were scumbed and subjected to bacteriological investigation, samples were collected from heart blood, liver, spleen, air sacs and pericardial sacs, and inoculated or streaked onto MaConky broth, MaConky agar and blood agar. Colonies suspected to be E.coli were subjected to biochemical and serological examination which showed that the isolated colonies were E. coli O2: K1 and O113: K 75 (Table 1).

In vitro – sensitivity test:

Antibiogram was carried out on the E.coli isolated strain against 9 antibiotics including ciprofloxacin which showed the largest inhibition zone of 29 mm (Table 2).

Minimum inhibitory concentration (MIC):

The result of MIC cleared that ciprofloxacin had lowest concentration (0.0312 µg/ml) that enough to inhibit the growth of the isolated field E. coli strains.

Pharmacokinetic properties:

Ciprofloxacin was detected in the serum of E.coli infected chickens for 24 hours after IV and oral administration of 10 mg /kg. b.wt. (Table 3 , Figs. 1 and 2). For compartmental analysis of serum ciprofloxacin concentration over time after IV administration, the data were best described by a two-compartment open model with an α of 1.933h⁻¹ and β equal to 0.115h⁻¹ (Table 4). The estimate of Co was 2.888 ug/ml and the volume of the central compartment (Vc) was computed as 3.463 L/kg . The noncompartmental Iv parameters of CLB ,Vd (area) and Vdss were computed 1.424L/kg, 12.285 L/Kg and 3.026 L/Kg, respectively. Serum concentration of ciprofloxacin after 10mg/kg b.wt. oral dosing were best described as a one – compartment open model. The serum concentration-time curve depicts a slow elimination slope. However, this terminal slope is actually reflective of the slow rate of absorption as the evidence by the tmax of 3.0 hours. The t_{0.5a} was computed as 1.619 h, and the t_{0.5e} was calculated to be 6.026 hours (Table 5) . Bioavailabilty was 75.9%.

DISCUSSION

In designing a dosage regimen for antimicrobial agents, mechanism of bacterial killing and postantibiotic effect (PAE) must be considered (Vogeleman and Craig, 1986; Vogeleman *et al.*, 1988; Dudley, 1991; Bergeron, 1992; Nightingle, 1993 and Crag, 1993). Antimicrobials that inhibit DNA gyrase (e.g. quinolones) have concentration-dependent bactericidal activity and induce PAE (Vogeleman and Craig, 1986; Vogeleman *et al.*, 1988; Bergeron, 1992 and Crag, 1993). Animal infection model used to study duration of in vivo PAE after exposure to fluoroquinolones used in human beings had suppression of bacterial growth for 1.9 to 7.5 hours in Enterobacteriaceae (Craig, 1993). Other factors documented to increase the duration of quinolone PAE are high drug concentration (maximal effect at 5 to 10 times MIC), long exposure time, and presence of neutrophils (Vogeleman and Craig, 1986; Schentag, 1991 and Craig, 1993).

In this study, after oral administration of 10mg/kg b.wt. of ciprofloxacin to E.coli naturally infected chickens, peak serum concentration C_{max} was 0.510 µg/ml (16.026 times MIC of E.coli isolates)

Also, oral administration of ciprofloxacin characterized by high bioavailability (75.9%), high volume of distribution (12.270 L/kg) and slow elimination rate (0.115h⁻¹) which indicated that ciprofloxacin was highly absorbed, easily penetrated all tissues and remain in the body above the MIC of E. coli isolates for 24 hours (C₂₄=0.050 µg/ml).

On the basis of recent trials in human beings (**Forrest *et al.*, 1993** and **Kung *et al.*, 1993**) and animal infection studies (**Drusano *et al.*, 1993**), investigators have proposed that the critical break point determining efficacy of quinolones is an AUC– to – MIC ratio which must be not less than 125.

In this study, the recommended dose of ciprofloxacin (10 mg/kg b.wt.), administered once daily would likely result in an AUC – to - MIC ratio greater than 125 (172.019) in E. coli infected chickens.

We conclude that, ciprofloxacin dose of 10 mg/kg b.wt. administered orally once daily to E. coli naturally infected chickens would likely achieve the target ratios of C_{max}-to- MIC greater than 10 necessary to minimize bacterial resistance, and AUC– to – MIC ratio greater than 125 to maximize clinical and microbiological cures .

REFERENCES

- Amsterdam, D. X. (1991):** Susceptability testing of antimicrobials in liquid media. In: Lorain 5th. ed. Antibiotics in laboratory medicine . 3 rd. ed. battimore : The Williams and wilkins Co 97– 98
- Atef, M.; Youssef, S. A. H.; Amer, A.M.M. and El-Banna, H.A.H. (1992):** Influence of E.coli infection on the disposition kinetic of nalidixic acid in broiler chickens. *Deutsch. tierarztl Wschr* 99 : 140-143.
- Baggot, J. D. (1978):** Some aspects of clinical pharmacokinetics in veterinary medicine . *J. Vet. Pharm. Therap.* 1,5-17 .
- Baggot, J. D. (1980):** Distribution of antimicrobial agents in normal and diseased animals. *J. Amer. Vet. Med. Asso.* 10 : 1085 – 1090 .
- Bauer, A. W. (1963):** The significance of bacterial inhibition zone diameters. A study of the factors influencing antibiotic sensivity tests. *Proceeding of the 3 rd International Congress Chemotherapy, Stuttgart .*
- Bennett, J.V.; Brodie, J. L. and Benner, E.J. (1966):** Simplified accurate method for antibiotic assay of clinical specimens . *Appl. Microbiol.* 14 : 170 – 177.
- Bergeron, M. G. (1992):** What preclinical data are needed to justify once-daily therapy ? *J Clin Pharm* 32 : 698 – 705.

- Campoli-Richards, D. M.; Monk, J.P.; Price, A.; Benfield, P.; Todd, P.A. and Ward, A. (1988):** Ciprofloxacin : A review of its antibacterial activity pharmacokinetic properties and therapeutic uses. *Drugs* 35 : 373 – 447.
- Crag, W. (1993):** Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens . *Eur. J. Clin. Microbiol. Infect. Dis.* s1 : 6 – 8.
- Craig, W. A. (1993):** Post- antibiotic effects in experimental infection models relationship to in vitro phenomena and to treatment of infections in man . *J. Antimicrob. Chemother.* 31:149 – 158.
- Cruickshank, R.; Duguid, R. P.; Maromion, B. P. and Swain, (1975):** *Medical Microbiology.* 12 th ed. Vol. 2 Published by Churchill livingstone edinburgh.
- Drusano, G. L.; Hooper, D. C.; Johndon, D. E. and Rosen, M. (1993):** Pharmacodynamics of a fluoroquinolones antimicrobial agent in a neutropenic rat model of *Pseudomonas* sepsis. *Antimicrob. Agents Chemother.* 37:483-490.
- Dudley, M. N. (1991):** Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. *Amer. J. Med.* 91 : 45S – 50S.
- Edwards, P. R. and Ewing, W.H.X. (1962):** Identification of Enterobacteriace 3 rd. ed. Burgess publishing co. Minneapolis. Minn USA .
- Forrest, A.; Nix, D.E. and Ballow, C.H. (1993):** Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients . *Antimicrob. Agents Chemother.* 37 : 1073 – 1081.
- Kauffman, F. (1969):** The bacteriology of Enterobacteriace. 2 rd. ed. Monksgard Copenhagen
- Kolmer, J.A.; Spoilding, E.H. and Ribinsmh, W. X. (1951):** Approved laboratory technique. 5 th ed. Applection Century-croftsi.N.C. New York .
- Kung, K.; Rioud, J.L. and Wanner, M. (1993):** Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs . *J. Vet. Pharm. Ther.* 16:462 – 468.
- Leggett, J.E.; Fantin, B. and Ebert, S. (1989):** Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh infection models. *J. Infect. Dis.* 159:281-292.
- Metzier, C.N. and Weiner, D. L. (1989):** PCNONLIN software for the statistical analysis of nonlinear models on micros. 3 rd. ed. version 3 USA .
- New, H. C.(1987):** New antibiotics Areas of appropriate use. *J. Infect. Dis.* 403-415 .

- Nightingale, C. H. (1993):** Pharmacokinetic considerations in quinolone therapy. *Pharmacotherapy* 13 : 34 – 38.
- Rosin, E.; Ebert, S. and Uphoff, T. S. (1989):** Penetration of antibiotics into the surgical wound in a canine model. *Antimicrob Agents Chemother* 33:700-704.
- Schentag, J.J.(1991):** Correlation of pharmacokinetic parameters to efficacy of antibiotics : relationships between serum concentrations , MIC values , and bacterial eradication in patients with gram – negative pneumonia. *Scand. J. Infect. Dis.* 74 : 218 – 234 .
- Snedecor, G.W. and Cochran, W.G. (1967):** *Statistical Method.* 6 th ed Lowastatr university Press Amer Iowa.
- Sojka, W.J.X. (1965):** E.coli in domestic animals and poultry . Commonwealth Agricultural boreaux. p. 157.
- Vogelman, B. and Craig, W. A. (1986):** Kinetics of antimicrobial activity. *J. Pediatr.* 108 : 835 – 840.
- Vogeleman, B.; Gudmundsson, S. and Leggett, J. (1988):** Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy with an animal model. *J. Infect. Dis.* 158 : 831 – 847.
- Wolfson, J.S. and Hooper, D.C. (1985):** The fluoroquinolones: structures. Mechanisms of action and resistance, and spectra of activity in vitro. *Antimicrob Agents Chemother.* 28:581-586.

The authors thanks Prof. Dr. Abdalh Metwally El-bauomy for his helpness in data analysis by using PCNONLIN program .

Table (1): Biochemical tests for identification of isolated E. coli.

Biochemical test	Result
Indole production	+
Methyl red	+
Nitrate	+
Simmon's citrate	-
Urea hydrolysis	-
H ₂ S production	-
Voges proskauer	-
Carbohydrate fermentation:	
- Lactose	+
- Glucose	-
- Mannitol	-

Table (2): Susceptibility of isolated E.coli from infected chickens to various antimicrobial agents.

Tested drugs	Disc Potency (µg)	Inhibition zone (mm)
Ciprofloxacin	5	29
Lincospectin	50/100	25
Ceftifour	10	20
Ampicillin	30	16
Gentamycin	10	15
Streptomycin	30	14
Erythromycin	15	10
Oxytetracycline	30	-
Lincomycin	15	-

Table (3): Serum concentration of ciprofloxacin (µg/ml) in E.coli infected chickens after a single oral or intravenous administration of 10 mg/kg b.wt. (X +S.E)

Hours after administration	Serum concentration (µg/ml)	
	Oral	Intravenous
0.10	0.110 + 0.010	2.492 + 0.096
0.25	0.128 + 0.011	2.021 + 0.125
0.50	0.164 + 0.015	1.480 + 0.080
0.75	0.211 + 0.021	1.140 + 0.023
1	0.265 + 0.019	0.895 + 0.065
2	0.439 + 0.023	0.586 + 0.033
3	0.510 + 0.043	0.479 + 0.040
4	0.500 + 0.040	0.427 + 0.035
6	0.399 + 0.032	0.339 + 0.019
8	0.317 + 0.020	0.270 + 0.026
10	0.252 + 0.020	0.214 + 0.016
12	0.200 + 0.016	0.170 + 0.012
24	0.050 + 0.014	0.043 + 0.015

Table (4): Pharmacokinetic variables of ciprofloxacin in E.coli infected chickens after a single IV administration of 10 mg/kg b.wt. (x + S.E.).

Parameter	Unit	Iv Administration
C ₀	µg/ml	2.888±0.193
A	µg/ml	2.212±0.035
A	h ⁻¹	1.933±0.070
t _{0.5 α}	h	0.359±0.033
B	µg/ml	0.676±0.029
B	h ⁻¹	0.115±0.014
t _{0.5 β}	h	6.026±0.106
K ₁₂	h ⁻¹	1.096±0.012
K ₂₁	h ⁻¹	0.541±0.030
K _{el}	h ⁻¹	0.411±0.032
V _c	L/kg	3.463±0.021
V _d (B)	L/kg	14.793±1.103
V _d (area)	L/kg	12.285±1.098
V _{dss}	L/kg	3.026±0.022
Cl _B	L/kg	1.424±0.091
AUC	µg.h / ml	7.081±0.087

Table (5): Pharmacokinetic variables of ciprofloxacin in E.coli infected chickens following a single oral administration of 10 mg/kg b.wt. (x + S.E)

Parameter	Unit	Oral administration
A	µg/ml	0.718±0.043
K _a	h ⁻¹	0.428±0.020
t _{0.5a}	h	1.619±0.086
C _{max}	µg/ml	0.510±0.018
C _{max} / MIC		16.346±1.190
C ₂₄	µg/ml	0.050±0.002
C ₂₄ /MIC		1.603±0.098
T _{max}	h	3.00±0.218
B	µg/ml	0.795±0.066
K _e	h ⁻¹	0.115±0.011
t _{0.5e}	h	6.026±0.041
V _C	L/kg	12.270±0.987
Cl _B	L/kg	1.411±0.012
AUC	µg. h/ml	5.367±0.473
AUC/MIC		172.019±12.001

- C_0 : drug concentration at zero time immediately after IV dosage.
- A and B: Zero - time intercepts of absorption and elimination phase.
- α or K_a : over all absorption rate constant .
- $t_{0.5 \alpha}$: absorption half - life .
- β or K_e : Over all elimination rate constant .
- $t_{0.5 \beta}$: elimination half – life.
- K_{el} : rate constant of elimination.
- K_{12} : rat constant of distribution from central to Peripheral compartment .
- K_{21} : rat constant of distribution from Peripheral to central compartment .
- V_c : apparent volume of central compartment.
- V_d : apparent volume of distribution.
- Cl_B : body clearance.
- C_{max} : maximum drug concentration.
- C_{24} : drug concentration at 24 hours.
- T_{max} : time at C_{max} .
- Auc : area under the curve.
- MIC : minimum inhibitory concentration.




Figure (1): semilogarithmic plot of mean \pm SD (n=5) serum drug concentrations ($\mu\text{g/ml}$) VS time (hours) in E.coli infected chickens given a single IV dose of ciprofloxacin (10mg/kg b. wt.)




Figure (2): semilogarithmic plot of mean \pm SD (n=5) serum drug concentrations ($\mu\text{g/ml}$) VS time (hours) in E.coli infected chickens given a single oral dose of ciprofloxacin (10mg/kg b.wt.).

الملخص العربي

الحركة الدوائية للسبروفلوكسايين في الدواجن المصابة بالقولون العصوي

محمد محمد احمد و عبد الحكيم محمد مصطفى

قسم الأدوية وقسم الدواجن - معهد بحوث صحة الحيوان بالزقازيق

تم دراسة الحركة الدوائية للسبروفلوكسايين في الدواجن المصابة بالقولون العصوي والتي تم الحصول عليها من احد المزارع التي تعاني من الاصابه بهذا الميكروب وذلك بعد اعطائها جرعه واحده عن طريق الوريد والفم (١٠ مجم/كجم وزن حي).

وقد وجد ان اقل تركيز للسبروفلوكسايين يلزم لمنع نمو الميكروب هو ٠,٠٣١٢ ميكروجرام / مل ، كما وجد بعد اعطاء الجرعه العلاجيه عن طريق الفم ان اعلى تركيز للسبروفلوكسايين في السيرم هو ٠,٥١٠ ميكروجرام /مل بعد ٣ ساعات ، في حين وصل التركيز الى ٠,٠٥٠ ميكروجرام /مل عند ٢٤ ساعة .

وتبين من هذه الدراسة ان فترة نصف العمر للسبروفلوكسايين بعد اعطائه بالطريقتين متساوية (٦,٠٢٦ ساعات) وان مدى استفادة الجسم من العقار بعد اعطائه عن طريق الفم هي ٧٥,٩% .

وقد استنتج من هذا البحث ان نسبة اعلى تركيز للسبروفلوكسايين في السيرم الى اقل تركيز يلزم لمنع نمو الميكروب تساوي ١٦,٣٤٦ (أكثر من ١٠ اضعاف) وهذه النسبة كافية لتقليل مقاومة الميكروب للعقار ، وكذلك نسبة المساحة تحت المنحنى الى اقل تركيز ينزرد لمنع نمو الميكروب تعادل ١٧٢,٠١٩ (اكثر من ١٢٥ ضعف) وهذه النسبة كافية لزيادة معدلات التماثل للشفاء الظاهري والقضاء على الاصابة البكتيرية .